Clinical trialNANo longer available
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- NA
- Status
- No longer available
- Study type
- Expanded access
- Sites
- 2
- Sponsor
- Industry
- Results posted
- No
- Last update
- 14 August 2020
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense. Since it is a heat-killed preparation, treatment is not associated with the potential side-effects of delivering live or attenuated organisms. Five studies with IMM-101 have been completed including a 110-patient randomised Phase II study in pancreatic cancer and exploratory studies in other solid tumours (melanoma, colorectal cancer and advanced melanoma).
Papers 2
- Registry-listed results paperRandomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. DOI 10.1038/bjc.2016.342↗
- BackgroundExtended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Inducti… DOI 10.7759/cureus.435↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.